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Background: Whether overweight or obese end stage renal disease (ESRD) patients are suitable for renal
transplantation (RT) is often debated. The objective of this review and meta-analysis was to systematically
investigate the outcome of low versus high BMI recipients after RT.
Methods: Comprehensive searches were conducted in MEDLINE OvidSP, Web of Science, Google Scholar, Embase,
and CENTRAL (the Cochrane Library 2014, issue 8). We reviewed four major guidelines that are available regarding
(potential) RT recipients. The methodology was in accordance with the Cochrane Handbook for Systematic
Reviews of Interventions and written based on the PRISMA statement. The quality assessment of studies was
performed by using the GRADE tool. A meta-analysis was performed using Review Manager 5.3. Random-effects
models were used.
Results: After identifying 5,526 studies addressing this topic, 56 studies were included. We extracted data for 37
outcome measures (including data of more than 209,000 RT recipients), of which 26 could be meta-analysed.
The following outcome measures demonstrated significant differences in favour of low BMI (<30) recipients:
mortality (RR = 1.52), delayed graft function (RR = 1.52), acute rejection (RR = 1.17), 1-, 2-, and 3-year graft survival
(RR = 0.97, 0.95, and 0.97), 1-, 2-, and 3-year patient survival (RR = 0.99, 0.99, and 0.99), wound infection and dehiscence
(RR = 3.13 and 4.85), NODAT (RR = 2.24), length of hospital stay (2.31 days), operation duration (0.77 hours), hypertension
(RR = 1.35), and incisional hernia (RR = 2.72). However, patient survival expressed in hazard ratios was in significant favour
of high BMI recipients. Differences in other outcome parameters were not significant.
Conclusions: Several of the pooled outcome measurements show significant benefits for ‘low’ BMI (<30) recipients.
Therefore, we postulate that ESRD patients with a BMI >30 preferably should lose weight prior to RT. If this cannot be
achieved with common measures, in morbidly obese RT candidates, bariatric surgery could be considered.Background
As the incidence of overweight and obesity rises globally,
so does the number of end stage renal disease (ESRD)
patients with obesity [1]. Renal transplantation (RT) is
the preferred therapeutic option for ESRD, however,
whether obese patients are suitable for RT is often
debated due to the higher risk of complications [2].
Several guidelines state that obesity is not considered
an absolute contra-indication, although patients with
a body mass index (BMI) above 40 or 45 should not
be considered for RT [3,4]. On the other hand, the* Correspondence: f.dor@erasmusmc.nl
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unless otherwise stated.guidelines state that if the transplant surgeon determines
that the body composition of the potential RT recipient
does not constitute an increased surgical risk, the patient
should be suitable for RT. However, this does not take
into account that it is not only the surgery itself that
poses a possible risk. Equally important is the incidence
of post-transplant complications in the obese recipient.
Observational studies in the general population have
demonstrated that obesity is an independent risk factor
for chronic vascular disease [5]. Obesity is also associated
with a number of risk factors for chronic vascular disease,
including hypertension, dyslipidaemia, and diabetes [6].
Of note, in general, the most important mortality and
morbidity post-transplant is due to cardiovascular com-
plications [7].l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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been associated with a higher incidence in obese recipi-
ents are delayed graft function (DGF), impaired graft
survival, longer hospital stay, higher costs, higher inci-
dence of new onset of diabetes after transplantation
(NODAT) and increased mortality [8-11]. Intuitively, all
overweight potential recipients should lose weight prior
to transplantation. Usually, dietary restriction is applied
under the supervision of a dietician. However, in most
cases, the desired result is not achieved, caused by sev-
eral factors such as the need for dialysis three times a
week, a low exercise tolerance, and comorbidities. In
case of peritoneal dialysis, patients are known to in-
crease in weight because the dialysate contains a high
concentration of dextrose [12]. The body absorbs some
of this dextrose during the dwell, which can lead to
weight gain. Bariatric surgery (in case of morbid obesity
or a BMI >35 with one or more comorbidities) could be
considered, as it has proven to be successful in weight
reduction in non-ESRD patients [13,14]. Few studies
are available regarding bariatric surgery pre- or post-
transplantation in (morbidly obese) ESRD-patients, how-
ever these all show promising results [15-17]. As has
been recently published by Gill et al. [18], the transplant
community needs to realize that even obese RT recipi-
ents have a significant survival benefit from transplant-
ation despite the reduced risk of death of obese dialysis
patients.
Recently, Nicoletto et al. [19] carried out a systematic
review and meta-analysis on the same topic, and con-
clude that obese patients have an increased risk for
DGF. However, they only included 21 studies and did
not include surgical outcome in these patients, which is
an important topic in our opinion, as patients are fre-
quently declined for RT because of the increased risk for
surgical complications.
The aim of the present systematic review and meta-
analysis is to give a more in-depth insight in (metabolic,
survival, and surgical) outcome of low (<30) versus high
(>30) BMI recipients after RT.
Methods
All aspects of the Cochrane Handbook for Interven-
tional Systematic Reviews were followed [20], and the
manuscript was written according to the PRISMA
statement [21].
Literature search strategy
Comprehensive searches were carried out in Embase,
MEDLINE OvidSP, Web of Science, Google Scholar,
CENTRAL (the Cochrane Library 2013, issue 5), and the
Transplant Library. The search was performed for arti-
cles published until August 2014 relevant to outcome
of kidney transplant recipients, both from a living ordeceased donor. No language restriction was applied.
Studies were included concerning patients that under-
went RT, in which the recipients were divided according
to BMI classification. As a cut-off value, a BMI of 30
was used to classify the included patients between ‘low’
(<30) and ‘high’ (>30) BMI, according to the definitions
of the World Health Organization [22]. Included out-
come measures were: mortality (defined as death within
follow-up of each study), patient survival at years 1, 2,
and 3, graft survival at years 1, 2, and 3, primary non-
function, DGF (in 10 out of 30 studies defined as the
need for dialysis within 7 days of transplantation), acute
rejection, chronic rejection, graft loss, estimated glom-
erular filtration rate, operation duration, length of
stay, lymphoceles, wound infection, incisional hernia,
hematoma, wound dehiscence, surgical adverse events,
NODAT, hypertension, and CMV infection. Search terms
for each search-engine are provided as Additional file 1.
Manual reference checks in included papers were per-
formed to check for potentially missing studies.
Guideline analysis
In addition to the literature search, we searched for
guidelines regarding (potential) RT recipients in order to
put the studies and their results in perspective. Specific-
ally, sections about (pre-operative) overweight or obesity
and RT suitability were reviewed.
Literature screening
Studies were evaluated for inclusion by two independ-
ent researchers (JAL, FJMFD) for relevance to the
subject. Study selection was accomplished through
several phases of screening. First, studies were ex-
cluded if they were one of the following: case-reports,
letters, editorials, case-series, animal studies, or if the
abstract revealed no relevance to the subject. For pub-
lications without abstract, the full text was acquired.
In the next phase, inclusion required that studies de-
scribed two or more groups of RT recipients divided
based on their BMI and described relevant outcome
measures.
Data extraction and critical appraisal
The level of evidence of each paper was established
using the GRADE tool [23]. The GRADE approach de-
fines the quality of a body of evidence by consideration
of within study risk of bias (methodological quality),
directness of evidence, heterogeneity, precision of effect
estimates, and risk of publication bias.
Statistical analysis
A meta-analysis was performed using Review Manager
version 5.3 (The Nordic Cochrane Centre, Copenhagen,
Denmark). Random-effects models were used to account
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outcome, results were presented in forest plots with risk
ratios or mean differences. Overall effects were deter-
mined using the Z-test; 95% CIs of these values were
given and P <0.05 was considered statistically significant.
Heterogeneity between studies was assessed by three
methods. First, a Tau2 test and a χ2 test were performed
for statistical heterogeneity, with a P <0.1 being consid-
ered statistically significant. Also, I2 statistics were used
to assess clinical heterogeneity, where an I2 of 0% to
40% is considered as low heterogeneity, 30% to 60%
as moderate heterogeneity, 50% to 90% as substantial
heterogeneity, and 75% to 100% as considerable het-
erogeneity. Where studies reported on two or more
high or low BMI groups, pooled mean estimates and
standard deviations were calculated. Group means
were weighted by the number of recipients in each
study group. Funnel plot analysis was used to assess
possible publication bias.
Results
We included four major guidelines that are currently
available regarding (potential) RT recipients: the Kidney
Disease Improving Global Outcomes (KDIGO) ‘Clinical
Practice Guideline for the Care of the Kidney Transplant
Recipient’ [24], ‘Assessment of the Potential Kidney
Transplant Recipient’ (5th edition, 2010) by the UK
Renal Association [25], the ‘Guideline on Kidney Donor
and Recipient Evaluation and Perioperative Care’ by
the European Renal Best Practice (ERBP) guideline
body [26], and Kidney Health Australia – Caring for
Australasians with Renal Impairment (KHA-CARI):
‘Recipient Assessment for Transplantation’ and ‘Obesity in
renal transplantation’ [27].
The KDIGO guidelines state that, in RT recipients,
obesity is associated with cardiovascular events and
mortality. Furthermore, they mention that there is
little reason to believe that weight reduction mea-
sures are not equally effective in obese potential RT
recipients as in the general population. However,
there is some indication that pharmacological and
surgical management of obesity may be more likely
to cause harm than in the general population. They
recommend that additional research is needed to de-
termine the effect of bariatric surgery on outcomes
in RT recipients.
The UK Renal Association guideline states that obese
patients (BMI >30 kg/m2) present technical difficulties
and are at increased risk of peri-operative complications.
They should be screened rigorously for cardiovascular
disease and each case should be considered individually.
Although obesity is not an absolute contra-indication to
transplantation, individuals with a BMI >40 kg/m2 are
less likely to benefit from RT.The ERBP guideline states that the association be-
tween BMI and patient survival after RT is controversial
based on current literature. Furthermore, it is recom-
mended that RT candidates with a BMI >30 kg/m2
should lose weight prior to RT.
The KHA-CARI guidelines recommend that obesity
alone should not preclude a patient from being consid-
ered for RT. Furthermore, they state that as a pre-
transplant BMI >40 kg/m2 may not be associated with a
survival advantage compared to remaining on dialysis,
the suitability for transplant should be carefully assessed
on an individual basis. Lastly, as patient and graft sur-
vival of obese transplant recipients may be mediated by
comorbid factors, particularly cardiovascular, they rec-
ommend screening of obese transplant candidates for
cardiovascular disease.
Literature search results
Out of 5,526 unique papers identified in the initial
search, 56 studies were included. The PRISMA flow dia-
gram for systematic reviews is presented in Figure 1.
Data for 37 outcome measures were extracted (repre-
senting data of more than 209,000 recipients) of which
26 could be meta-analyzed. The characteristics of the in-
cluded studies are presented in Table 1. The assessment
of the quality of the included studies is presented in
Figure 2.
Although the search could have identified randomized
controlled trials, only observational studies were found,
as randomized controlled trials addressing this topic do
not seem to be feasible.
Survival outcome parameters
Mortality The number of deceased patients was stud-
ied in 16 studies including a total of 5,489 RT recipi-
ents [10,31,33,39,40,42,45,46,48,50,55,57,59,65,72,75]. The
overall risk ratio was 1.52 (confidence interval (CI), 1.14–
2.03; P = 0.004, I2 = 47%; P = 0.02) for high BMI recipients
(Figure 3). Five studies assessed the mortality rate in a
regression model [9,32,41,42,62]. Overall, there were no
significant differences with an overall hazard ratio of 1.01
(CI, 0.89–1.15; P = 0.87, I2 = 87%; P <0.01). Massarweh
et al. [55] also expressed mortality in odds ratios; OR, 1.39
(CI, 0.43–4.49; P = 0.58, I2 not applicable).
Patient survival (1-, 2-, and 3-year) One-year patient
survival was analysed in 18 studies and showed better
survival for low BMI recipients (risk ratio (RR) = 0.99,
CI, 0.99–0.99; P <0.001, I2 = 0%; P = 0.45) [2,9,10,28-31,
34,39,44-46,50,51,54-56,62]. At 2 years, seven studies
showed a significant difference between recipient groups,
again in favour of low BMI recipients (RR = 0.99, CI, 0.97–
1.00; P = 0.04, I2 = 7%; P = 0.37) [10,29,44,45,50,62,78]. The
3-year patient survival was investigated in 12 studies,
Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart of the systematic literature search.
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(CI, 0.95–0.99; P = 0.004, I2 = 61%; P = 0.003; Figure 4)
[2,10,29-31,34,40,44,50,54,62,64]. Interestingly, the five
studies that included BMI in regression analyses
showed that a higher BMI is associated with a higher
patient survival with an overall hazard ratio of 0.93
(CI, 0.89–0.97; P <0.001, I2 0%; P = 0.68) [2,29,30,51,53].
Grosso et al. [42] calculated an odds ratio of 27.98
(CI, 3.25–240.89; P = 0.002, I2 not applicable) in high
BMI recipients.
Graft survival (1-, 2-, and 3-year) Twenty-four studies
investigated 1-year graft survival and showed a better
graft survival in recipients with a low BMI (RR = 0.97,
CI, 0.96–0.99; P <0.001, I2 = 11%; P = 0.32) [9,10,28-31,
33,39,44-46,48,50,51,53,54,56,57,59,60,62,63,68,75]. Eleven
studies assessed the 2-year graft survival [10,25,33,44,
45,48,50,57,62,63,78]. The overall risk ratio was 0.95
(CI, 0.93–0.98; P = 0.002, I2 = 30%; P = 0.16). The 13
studies that analysed 3-year graft survival showed an
overall risk ratio of 0.95 (CI, 0.91–0.98; P = 0.006, I2 = 50%;
P = 0.02) [10,29-31,33,40,44,50,54,62-64,75]. In each year
studied, graft survival was in favour of low BMI recip-
ients (Figure 5). Seven studies included BMI as aparameter in regression analyses showing no signifi-
cant relation between BMI and graft survival. The
overall hazard ratio was 1.00 (CI, 0.96–1.04; P = 0.98,
I2 54%; P = 0.04) [2,9,29,30,48,52,53]. Grosso et al.
[42] calculated an odds ratio (OR = 0.98, CI, 0.13–7.39;
P = 0.98, I2 not applicable).
Kidney function outcome parameters
Delayed graft function The incidence of DGF was
assessed in 30 studies encompassing a total of 15,262
recipients [1,4,28,29,31,33,34,36,38-40,42,43,46-48,50,53,
56,57,59,60,64,66,69,71,75,77,78]. The overall risk ratio
was 1.52 (CI, 1.35–1.72; P <0.001, I2 = 50%; P = 0.001;
Figure 6). Six studies assessed DGF in ORs using a BMI
of 30 as cut-off value [2,8,32,35,58,73]. The overall OR
when pooling these studies was 1.38 (CI, 1.20–1.59;
P <0.001, I2 = 92%; P <0.01). The pooled OR when using
a BMI of 35 as a cut-off was 1.96 (CI, 1.69–2.28;
P <0.001, I2 = 32%; P = 0.23) [8,35,58].
Acute rejection The incidence of acute rejection was
investigated in 22 studies [4,10,28,33,36,38,39,43,46,48,
50,55-57,59-61,64,69,72,75,76]. Twelve studies showed a
lower risk ratio on acute rejection in low BMI recipients.
Table 1 Overview of the included studies in the
systematic review
Reference Country Year BMI groups n
Aalten [9] The Netherlands 2006 <30 1,871
≥30 196




Bardonnaud [29] France 2012 <30 179
≥30 21




Bennett [31] USA 2011 <30 439
30.1–34.9 109
>35 89








Chow [33] China 2006 <25 113
≥25 37



















Table 1 Overview of the included studies in the
systematic review (Continued)
Espejo [1] Spain 2003 <30 40
≥30 40
Farooq [38] USA 2014 <36 27
≥36 27
Furriel [39] Portugal 2011 18.5–24.9 295
25.0–29.9 127
≥30 26
Gill [40] USA 1993 <27 85
>30 85
Gill [41] USA 2013 Not reported





Grosso [42] Italy 2012 <25 122
25–30 190
>30 64




Halme [44] Finland 1995 20–25 235
>30 47
Holley [45] USA 1990 ≤27 (male) 50
≤25 (female)
≥30 46
Howard [46] USA 2002 <25 457
25–29.9 278
≥30 98




Johnson [48] Australia 2002 ≤30 434
>30 59
Kamali [49] Iran 2010 <30 146
>30 34
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Table 1 Overview of the included studies in the
systematic review (Continued)
Lynch [51] USA 2009 <20 33
20–30 491
≥30 345
McGee [52] USA 2008 <25 Not reported
25–29
≥30




Marks [54] USA 2004 ≤28 224
≥35 23
Massarweh [55] USA 2005 <30 137
≥30 56
Mehta [56] USA 2007 <30 37
≥30 16
Meier-Kriesche [10] USA 1999 ≤25 240
>25 165
Modlin [57] USA 1997 <27 127
>30 127










Papalia [60] Italy 2010 18.5–25 110
25–30 84
Patel [61] USA 2011 <30 315
≥30 160
Pieloch [62] USA 2014 18.5–24.9 24,077
35–40 6,055
Pirsch [63] USA 1995 <27.5 466
27.5–30 59
>30 59
Powers [64] USA 2010 <25 34
25–30 34
>30 20
Table 1 Overview of the included studies in the
systematic review (Continued)













Schwarznau [68] USA 2008 <30 56
>30 25
Singh [69] Canada 2005 ≤30 35
>30 33









Turner [4] USA 2007 <30 753
≥30 241
Walczak [72] USA 2010 <30 61
>30 46
Weissenbacher [73] Austria 2012 <25 746
>25 367
Wolyniec [74] Poland 2011 <30 29
≥30 29
Yamamoto [75] USA 2002 <30 28
>30 28
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Figure 2 Summary of findings table of extended criteria in live
kidney donation generated by the GRADE tool.
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1.17 (CI, 1.01–1.37; P = 0.04, I2 = 38%; P = 0.04; Figure 7).
Gore et al. [8] assessed the incidence of acute rejec-
tion in OR as 1.19 (CI, 1.11–1.28; P <0.001, I2 not
applicable).
Other outcome parameters showing no significant differ-
ences in kidney function outcome parameters are out-
lined in Table 2.
Surgical outcome parameters
Operation duration Only three studies investigated the
operation duration in low versus high BMI recipients,
showing a mean difference of 0.77 hours (CI, 0.15–1.40),
with a statistically significant difference (P = 0.02, I2 = 87%;
P <0.01; Figure 8) [40,45,48].
Length of stay The length of hospital stay was assessed
in 11 studies [28,29,39,40,43,45,54,56,57,69,78]. All stud-
ies but two showed a mean length of stay in favour of
low BMI recipients [39,40]. The overall mean difference
was 2.31 days (CI, 0.93–3.69; P = 0.001, I2 = 48%, P = 0.04;
Figure 8).
Wound infection The incidence of wound infections
was studied in 13 studies with a total of 4,504 recipients
[31,40,45,48,51,54-56,59,61,63,69,72,78]. The overall risk
ratio of this outcome was 3.13 (CI, 2.08–4.71; P <0.001,
I2 = 65%; P <0.01; Figure 9).
Incisional hernia Two studies assessed the incidence of
incisional hernias [55,69]. The overall risk ratio was 2.72
(CI, 1.05–7.06; P = 0.04, I2 = 0%; P = 0.82; Figure 9).
Wound dehiscence Six studies reported the incidence
of wound dehiscence including 3,922 recipients [29,43,
48,51,69,72]. The overall risk ratio was 4.85 (CI, 3.25–
7.25; P <0.001, I2 = 0%; P = 0.75; Figure 10).
Surgical adverse events Five studies investigated surgi-
cal adverse events, such as urologic, vascular, and haem-
orrhagic complications [28,36,39,74,77]. The overall risk
ratio was 1.30 (CI, 1.05–1.62; P = 0.02, I2 = 0%; P = 0.65;
Figure 10).
Other outcome parameters showing no significant dif-
ferences in surgical outcome parameters are outlined in
Table 3.
Metabolic outcome parameters
NODAT Six studies including 4,111 recipients investi-
gated the incidence of new onset diabetes after trans-
plantation [33,40,43,45,59,60]. Overall, a risk ratio of
2.24 (CI, 1.46–3.45; P <0.001, I2 = 53%; P = 0.06) was
found.
Figure 3 Forest plot of comparison: high versus low BMI recipients; outcome: mortality.
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hypertension in different BMI groups including 194 pa-
tients [60]. High BMI recipients had a higher risk
on hypertension with a risk ratio of 1.35 (CI, 1.09–1.67;
P = 0.005, I2 not applicable).
Other outcome parameters
Cytomegalovirus (CMV) infection The incidence of
CMV infection was addressed in two studies [33,72].
Overall, the risk ratio was 0.69 (CI, 0.20–2.37; P = 0.56,
I2 = 14%; P = 0.28) in favour of low BMI recipients.
Discussion
With this meta-analysis, we aimed to determine
whether guidelines or policy should be revised with
respect to suitability for RT of overweight and obese
(potential) recipients, since this is often debated.
There are several central questions behind this need
for additional insight. Should obese ESRD-patients be
transplanted at all? Are we and are these patients
aware of all possible risks? Should we emphasize the
need for weight loss, or even advise bariatric surgery
before RT, and to whom?
The worldwide prevalence of obesity is rising, lead-
ing to an increasing number of patients with cardio-
vascular comorbidity, diabetes (metabolic syndrome)
and, consequently, ESRD [79-81]. As RT is the
golden standard in treating these patients, a good
understanding of the consequences of transplanting
overweight and obese ESRD-patients is needed. Sev-
eral reviews have been written regarding this topic[82-93]. The KDIGO-guidelines state that observa-
tional studies report an association between obesity
and mortality in RT recipients. The present study is
the first meta-analysis investigating several (metabolic,
survival, and surgical) outcome measures, and pooling
data from a large number of studies (n = 56, including
over 209,000 recipients).
Nicoletto et al. [19] recently published a systematic
review and meta-analysis regarding this very subject.
Their main finding was that recipient obesity is asso-
ciated with an increased rate of DGF and that there
was no association between obesity and acute rejec-
tion. One of the limitations of their study is that they
included only 21 studies, whereas we included 56
publications. This could be explained by the fact that
fewer databases have been searched by the authors
(MEDLINE, EMBASE, and the Cochrane Library)
than we did (Web of Science, Google Scholar, and
the Transplant Library). Furthermore, the authors did
not describe if any study was excluded based on the
quality assessment of the Newcastle-Ottawa Quality
Assessment Scale or the GRADE tool. Interestingly,
the authors observed that studies published after
2003 show no differences in survival between BMI
groups. Although they state that 2003 was used as a
cut-off because of the fact that included patients
were transplanted before 2000, they do not provide
an explanation as to why obesity would pose a prob-
lem before 2000. In our opinion, other factors may
contribute to this result, such as the fact that live
kidney donation has increased over the years, providing
Figure 4 Forest plot of comparison: high versus low BMI recipients; outcome: patient survival at 1, 2, and 3 years.
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Figure 5 Forest plot of comparison: high versus low BMI recipients; outcome: graft survival at 1, 2, and 3 years and hazard ratio of graft survival.
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Figure 6 Forest plot of comparison: high versus low BMI recipients; outcome: delayed graft function.
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thus, patient survival. Moreover, they did not analyse
surgical outcome measures as wound infection and
dehiscence. In our opinion these are important out-
comes that should also be included in the informed
consent procedure for the recipients. Finally, we have
included a meta-analysis of hazard ratios of graft and
patient survival in the included studies, showing
more clearly that the BMI itself may not be the
cause of worse outcome in RT recipients but rather
other comorbidities associated with obesity such as
diabetes or (cardio-)vascular disease. Perhaps differ-
ent lifestyle recommendations should be provided to
patients who remain on dialysis versus those who
will be transplanted [94].
Our results clearly show that, in recipients with a
higher BMI, graft and patient survival are worse, at
least up to 3 years after transplantation. Interestingly,
in regression analyses, regarding patient survival,
having a higher BMI seems to be associated with ahigher patient survival, and regarding graft survival
there appears to be no significant relation with the
BMI. This could be explained by the ‘obesity para-
dox’, an interesting phenomenon that has been de-
scribed for haemodialysis patients [93], suggesting
that patients on haemodialysis with a higher BMI
tend to have an improved survival benefit. However,
the improved survival benefit is associated with
higher costs, more complications, and worse outcome
after transplantation [95]. On the other hand, and
perhaps most importantly, obese RT recipients still
demonstrate significant survival benefit from trans-
plantation compared to dialysis [18].
The kidney function outcome parameters show that
the incidence of DGF and acute rejection is higher in
high BMI recipients. A possible explanation is that
the operation duration is longer in recipients with a
higher BMI, which in itself is associated with higher
DGF-rates [96]. The increased incidence of acute re-
jection might be explained by the fact that obesity is
Figure 7 Forest plot of comparison: high versus low BMI recipients; outcome: acute rejection.
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sponses, potentially impacting allorecognition and
alloimmunity [97]. Another possibility is the in-
creased finding of (not clinically relevant) rejection
because of the higher incidence of biopsies in case of
DGF.
Regarding the metabolic outcome parameters, in-
creasing BMI shows a significant correlation with the
development of NODAT and hypertension, which is
not surprising, knowing that overweight and obesity
are common risk factors for developing these comor-
bidities [92,98].Table 2 Outcome parameters with no significant differences
Outcome
parameter
Studies RR (CI) P value
Primary non
function
3 [36,39,46] 2.53 (0.72–8.92) 0.15
Chronic rejection 2 [39,46] 0.18–3.54 0.76
Graft loss 5 [42,48,51,59,75] 1.14 (0.87–1.50) 0.34
Mean difference (CI)
eGFR year 1 3 [4,28,70] 7.53 mL/min (-3.17–18.24) 0.17
eGFR year 3 2 [33,70] -3.90 mL/min (-11.38–3.58) 0.31
eGFR year 5 1 [70] -0.10 mL/min (-0.24–9.04) 0.98
eGFR, Estimated glomerular filtration rate; RR, Risk ratio; CI, Confidence interval.All surgical outcome measures are significantly in
favour of recipients with a low BMI, with exception of
the incidence of hematoma and lymphoceles. A pos-
sible explanation could be that the latter two compli-
cations are not necessarily influenced by overweight
or body composition, in contrast to wound dehis-
cence or hernias [99,100].
Although a large part of our systematic review con-
cerns long-term outcome measures, we should bear in
mind that the perioperative (surgical) outcome mea-
sures are of great importance. Many RT candidates
with a high BMI are declined because the concern of
possible surgical difficulties and inherent complica-
tions. As confirmed by the results of the meta-
analysis, this concern is justified. Therefore, high BMI
RT candidates should be referred to tertiary referral
centres to centralise knowledge about and experience
with this patient category, especially on a transplant
surgical level. Additionally, it is another motivator to
encourage RT candidates to lose weight prior to trans-
plantation, ideally several years before the operation.
Nephrologists can play a crucial and proactive role in
this process.
In summary, we conclude that obesity prior to RT
leads to impaired outcome after RT. Losing weight prior
to transplantation might be of great importance,
Figure 8 Forest plot of comparison: high versus low BMI recipients; outcome: operation duration and length of stay.
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ESRD patients who remain dependent on dialysis
[101]. However, one should bear in mind that, even if
sufficient weight loss cannot be achieved before trans-
plantation, transplantation still leads to enormous ad-
vantages in terms of survival, health, and quality of life
[18]. We have recently performed a study showing that
patients who are deemed unsuitable for RT because of
high BMI in one centre have excellent outcome when
transplanted in a tertiary high-volume centre (Glijn
et al., manuscript in preparation). For overweight or
obese recipients that will be transplanted, conventional
methods to lose weight, such as dietary advice, might
not lead to the desired (or sufficient) effect [16,46,102].
Even though some weight loss might be achieved, after
transplantation, the weight is often regained, possibly
caused by the metabolic changes that may result in better
nutrient absorption and/or reduced energy expenditure
with improved renal function after transplantation. Fur-
thermore, the increased quality of life may lead to a lar-
ger food intake [94,103].
Another, more effective, method to lose weight
prior to or post-transplantation is bariatric surgery.
Some studies have already been performed showing
promising results [15-17,104-107]. Furthermore, it is
already stated by several guidelines that any person
with a BMI above 40, or a BMI higher than 35 withcomorbidities, should be advised to undergo bariatric
surgery [108-110] since it has proven to resolve
obesity-related comorbidities like diabetes, hyperten-
sion, sleep apnoea, and asthma and reduces mortality
rates. An issue of concern, however, is whether an
ESRD-patient is fit enough to undergo a risk redu-
cing operation with the risk of complications in it-
self. In general, the complication and mortality rates
after bariatric surgery have declined greatly over the
years to about 0.3% [111]. A few studies on bariatric
surgery in ESRD-patients show low complication and
90-day mortality rates close to 0% [15,16,112-114].
This is important to acknowledge because survival of
patients on dialysis is far worse compared to the sur-
vival after RT. [18] Therefore, every possible RT can-
didate should be carefully assessed to see if possible
complications of bariatric surgery, although being
very low, would not pose a risk for the transplant-
ation. In our opinion, every obese recipient should
be informed about this possibility, being aware of
possible risks. A clinical trial is ongoing to investi-
gate whether bariatric surgery before RT has benefits
(ClinicalTrials.gov, number NCT01913392).
Limitations
It has to be acknowledged that a systematic review
and meta-analysis can only be as good as the quality
Figure 9 Forest plot of comparison: high versus low BMI recipients; outcome: wound infection and incisional hernia.
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bias have been introduced in this analysis. The indi-
vidual studies are prone to sampling bias because of
the fact that they are observational studies. It is pos-
sible that, due to publication bias, the results have
become skewed. However, based on funnel plot ana-
lyses (data not shown), we can safely state that publi-
cation bias is minimal. Another limitation is that not
all studies have clearly specified the definition of cer-
tain outcome measures. For example, not all studies
mention whether or not cases of acute rejection are,
in fact, biopsy proven or the used definition of DGF.
This may introduce bias in the analyses leading to
heterogeneity. Moreover, only a few studies defined
whether the transplanted kidneys were from live or
deceased donors (donation after circulatory death or
donation after brain death), which is a confounding
factor in the pooled analysis of DGF. It would be in-
teresting to have this specific information, to see
whether the hypothesis that high BMI recipients have
better outcome when receiving a kidney from a livingdonor or a standard criteria ‘donation after brain
death’ donor kidney can be confirmed. In line of this
limitation, also the ‘pre-transplant’ status of a recipi-
ent is of importance; whether he or she was trans-
planted pre-emptively or was on haemo- or peritoneal
dialysis prior to transplantation has an impact on the out-
come after RT.
It would be interesting if future studies would in-
clude other parameters that take into account the fat
distribution of a recipient, as the BMI does not; for
example, the waist circumference or hip-waist-ratio
[115]. It could be that outcome would change if
these parameters were correlated to outcome of RT
recipients.
Conclusions
Based on our results, we make the following
recommendations:
 RT candidates should not be excluded for
transplantation on the basis of BMI alone.
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referred to high-volume/tertiary referral centres in
order to keep knowledge about these category of
patients centralized.
 Informed consent procedures for obese RT candidates
should include the risk profiles associated with obesity
and RT outcome.
 Both patients and clinicians should be aware of the
importance of weight loss prior to transplantation.
 (Morbidly) obese RT candidates should be informed
about all possible weight reduction methods,
ranging from dietary restriction under supervision of
a dietician to the option of bariatric surgery.
○ Obese RT candidates with a BMI between 30
and 35 should be referred to conventional methods
of weight reduction, with help of a dietician.
○ Obese RT candidates with a BMI >35 and
comorbidities or a BMI >40 should be referredble 3 Outcome parameters with no significant
ifferences
utcome parameter Studies RR (CI) P value
mphoceles 4 [29,40,69,72] 1.74 (0.74–4.11) 0.20
matoma 5 [48,55,69,72,78] 0.89 (0.34–2.34) 0.82
, Risk ratio; CI, Confidence interval.for bariatric surgery, based on bariatric
guidelines. Based on our experience, this
could pose some difficulties for dialysis
patients because of the required diet prior to
bariatric surgery and age limits for bariatric
surgery. Some bariatric centres have a
maximum age limit of 60 for bariatric
surgery. However, a large part of ESRD
patients is over 60 years old. For these
reasons, in our opinion, ESRD patients with
morbid obesity cannot be compared to
‘regular’ morbid obese individuals.
 Ideally, in high BMI RT candidates, the process of
weight reduction should be initiated several years
before RT to ensure an adequate time period for
remedial measures to become effective.
 Despite the poorer outcome of RT in these patients,
the survival benefit of RT over dialysis needs to be
emphasized. Therefore, we need to maximize our
efforts for obese ESRD patients to get access to RT,
and develop strategies to reduce the risks associated
with RT in this patient category.
 Innovations in surgical techniques should be
stimulated. For example, robot-assisted techniques
for implantation could be promising for this specific
patient category [116].
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